​

Funding Round

Series B - Rapport Therapeutics

Series B - Rapport Therapeutics

Investment Firm

Overview

Rapport Therapeutics is a clinical-stage biotechnology company that discovers and develops precision medicines for neurological disorders.

Announced Date

Aug 23, 2023

Funding Type

Series B

Highlights

Location

United States, North America

Social

Investor Lead

Cormorant Asset Management

Cormorant Asset Management

Cormorant Asset Management is a early_stage_venture and late_stage_venture and post_ipo and private_equity and venture firm.

Participant Investors

9

Investor Name
Participant InvestorSofinnova Investments
Participant InvestorT. Rowe Price
Participant InvestorARCH Venture Partners
Participant InvestorThird Rock Ventures
Participant InvestorFidelity

Round Details and Background

Rapport Therapeutics raised $150000000 on 2023-08-23 in Series B

Rapport Therapeutics is a clinical-stage biotechnology company that discovers and develops precision medicines for neurological disorders.

Company Funding History

2

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Mar 07, 2023
Series A - Rapport Therapeutics
3-100.0M
Aug 23, 2023
Series B - Rapport Therapeutics
11-150.0M

Recent Activity

There is no recent news or activity for this profile.